Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as APD371
Olorinab · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Olorinab | DRUG | Olorinab active treatment for 8 weeks. |
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
Olorinab is an investigational small molecule being studied for Crohn's disease, specifically for abdominal pain in people with the condition. It has been evaluated in a Phase 2 clinical trial in participants with Crohn's disease experiencing abdominal pain. It is not an approved therapy and remains in clinical development.
Olorinab targets CNR2, the cannabinoid receptor 2, and acts as an agonist at that receptor. By binding and activating CNR2, the drug is designed to act on cannabinoid receptor signaling. CNR2 agonism is the mechanism under investigation for reducing abdominal pain in Crohn's disease.
Olorinab is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating the compound in Crohn's disease. The drug is an investigational small molecule in the gastrointestinal therapeutic area.
Olorinab is in Phase 2 development. It has completed one Phase 2 trial in Crohn's disease and is not approved by the FDA. No active trials are currently listed for the program, and the compound remains investigational rather than an available treatment.
Olorinab has been studied in one completed Phase 2 trial, NCT03155945, titled Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain. The trial enrolled 14 participants, was uncontrolled, and was not randomized or double blinded.
Yes, Olorinab is also known as APD371. The Phase 2 trial NCT03155945 refers to the compound as APD371, while Olorinab is the current name for the same investigational small molecule targeting CNR2. Both names refer to the same drug candidate.